BridgeBio Pharma, Inc. (BIT:1BBIO)
54.12
0.00 (0.00%)
At close: Oct 31, 2025
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $120.70M USD in the quarter ending September 30, 2025, with 4,318.01% growth. This brings the company's revenue in the last twelve months to $353.78M, up 62.46% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$353.78M
Revenue Growth
+62.46%
P/S Ratio
34.71
Revenue / Employee
$484.63K
Employees
730
Market Cap
10.47B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Stellantis | 146.12B |
| Eni S.p.A. | 86.56B |
| Enel SpA | 77.79B |
| Assicurazioni Generali | 56.79B |
| Intesa Sanpaolo | 25.38B |
| UniCredit | 24.85B |
| Prysmian | 19.85B |
| Leonardo S.p.a. | 18.70B |